Several non-hepatocellular cancers were linked with hepatitis B virus (HBV) infection. This study was aimed to quantify the potential associations between HBV infection and multiple non-hepatocellular cancers. Continuous cases, including 5,715 noncancer and 40,963 cancer cases diagnosed from 2008 to 2014 in Sun Yat-sen University Cancer Center were analyzed. HBV DNA and hepatitis B core antigen (HBcAg) were examed in gastric cancer tissues by polymerase chain reaction and immunohistochemical staining. After adjusting for age, sex, year of diagnosis, smoking, drinking and family history of cancer, significant associations were found between serum HBsAg and frequently reported HBV-related non-hepatocellular cancers, including non-Hodgkin's lymphoma, cholangiocarcinoma and pancreatic cancer [adjusted odds ratio (AOR) and 95% confidence interval (CI): 1.89 (1.65-2.16)], as well as total other non-hepatocellular cancers [AOR and 95% CI: 1.12 (1.03-1.22)]. The median ages at diagnosis, all-cause death and cancer-specific death of serum HBsAg positive cancer patients were all significantly younger than those with serum HBsAg negative. HBV DNA was detected in 12.4% (34/275) gastric cancer tissues and HBcAg was most commonly detected in lymphocytes. This was the first report that HBV infection had a modest but significant nonspecific association with total non-hepatocellular cancers. Median age at diagnosis and death was significantly younger in serum HBsAg positive cancer patients. The underlying mechanism needs further investigation.
Hodgkin's lymphoma (NHL), 3 ,4 cholangiocarcinoma 5 and pancreatic cancer. 6, 7 Hepatitis C virus (HCV) is also an important etiology of HCC. 2 It has been demonstrated to be associated with not only increased risks of NHL, 8 cholangiocarcinoma and pancreatic cancer, 9 but also increased all-site cancer incidence and cancer-specific mortality. 10, 11 Meanwhile, patients with HCV infection are significantly younger at cancer diagnosis and death. 11 There has been several sporadic reports about the associations of HBV infection with gastric cancer 12, 13 and nasopharyngeal carcinoma. 14 Considering the high prevalence of HBV infection, it is important to quantify the potential associations between HBV infection and non-hepatocellular cancers.
In a national survey in 1992, the seroprevalence rate of HBsAg was 9.8% in China, and it decreased to 7.2% in 2006 owing to HBV vaccination program by the Chinese government since 1992. 15 Nevertheless, China was still a high endemic area of HBV infection in recent years. This study is aimed to investigate the potential role of HBV infection in multiple cancers with a large Chinese patient cohort.
Material and Methods

Ethics statement
All patients signed the informed consent for their information to be stored and analyzed in the hospital database. The study was approved by the ethics committees in Sun Yat-sen University Cancer Center (SYSUCC). It was conducted in accordance with the ethical standards of the World Medical Association Declaration of Helsinki.
Study population and data extraction
All data was extracted from electronic information systems which launched in 2007 in SYSUCC, including Electronic Medical Record (EMR) system and Laboratory Information System (LIS). The patients' clinical characteristics (i.e., age, sex, diagnosis, year of diagnosis and survival status) were extracted from EMR system, while serous test results for HBsAg, HCV core antigen (HCV-cAg), human immunodeficiency virus (HIV) antibody and antigen were extracted from LIS. Information about smoking, drinking and family history of cancer, which was stored in EMR system since late 2011, was also extracted for analysis. To ensure the quality of the extracted data, the data before 2008 (i.e., the first year of introducing the system) was excluded in our study considering the pilot application. There were 148,421 individual original records extracted from the information system of SYSUCC from January 2008 to December 2014. For duplicate cases who were identified by the same medical record number and the International Classification of Diseases-10 codes, only the first record of hospitalizations was retained. The same patients hospitalized for different diseases were recognized as different cases. However, for repeated admissions of the same patients with both malignant and non-malignant diagnoses, the records with non-malignant ones were excluded. In addition, cases with indefinite diagnoses and borderline tumors were also excluded. After further exclusion of cases without information for serum HBsAg, a total of 9,691 non-cancer and 68,038 cancer cases were identified. Among them, there were 5,715 non-cancer and 40,963 cancer cases with available information for smoking, drinking and family history of cancer.
Serologic assay for HBsAg, HCV-cAg, HIV antibody and antigen
At the first visit in our hospital, all patients received routine serum tests for HBV, HCV and HIV infection. Enzymelinked immunosorbent assay was applied for routine test for serum HBsAg. Serum samples were collected and centrifuged at 3,000 rpm for 15 min, and then were used for the test. The diagnostic kit, which had been approved for clinical diagnostic usage, was bought from Shanghai Kehua Bioengineering Company. Qualified positive and negative control serum provided by the Ministry of Health of the People's Republic of China was used in this test to ensure the accuracy of the test. anti-sense, 5 0 -GGTCGGTCGTTGACATTGCT-3 0 . GoTaq V R Green Master Mix (Promega, Madison, WI) was used for PCR amplification. The PCR products were analyzed by electrophoresis in agarose gels stained with ethidium bromide.
The paraffin-embedded tissue blocks of HBV DNA positive patients were cut into 4-mm sections. The immunohistochemical staining of HBcAg was performed with a HBcAg rabbit antibody (Abcam, ab7841) according to a previously described method. 16 Moderate to strong cytoplasmic and/or nucleus staining in 15% cells was considered to be positive as described previously. 17 
Follow-up of cancer patients
All cancer patients were advised to receive regular follow-up according to the respective clinical guidelines. For those who did not visit our hospital as scheduled, telephone follow-ups were conducted to obtain the treatment information and living status. All follow-up results were stored in the information system.
Statistical analysis
Univariate and multivariate binary logistic regression analysis was used to analyze the associations of serum HBsAg (-/1) with cancers. Differences of age at diagnosis and death between serum HBsAg positive and negative cancer patients were compared using non-parametric test. The statistical analyses were performed with SPSS for Windows V.13.0 (SPSS, Chicago, IL). A two tailed p values <0.05 was considered statistically significant.
Results
Basic characteristics of the study populations Table 1 showed the basic characteristics of the 5,715 noncancer and 40,963 cancer cases, which were finally included to quantify the potential associations between HBV infection and cancers. The serum positive rates of HBsAg were 12.7 and 20.6% in non-cancer and cancer population, respectively. There were more male and older (> 52 years) cases in cancer population. In addition, more cases with a history of smoking, drinking and family history of cancer were found in cancer population. Basic characteristics of serum HBsAg negative and positive cancer population were listed in Supporting Information Table 1 . Of 40,963 cancer cases, there were 8,418 (20.6%) cases with positive serum HBsAg. The median age was, respectively, 54 and 50 years old for serum HBsAg negative and positive cancer population. There were more males, more patients with a history of smoking and drinking in serum HBsAg positive cancer population.
The associations of serum HBsAg positivity with cancers
In this study, according to the correlation with HBV infection, the general cancer population was classified into three subtypes: HCC, other HBV-related cancers (frequently reported HBV-related non-hepatocellular cancers, including NHL, cholangiocarcinoma and pancreatic cancer), and other cancers (all the rest non-hepatocellular cancers).
The 5,715 non-cancer and 40,963 cancer cases with available information for not only serum HBsAg, but also behavior (smoking, drinking) and hereditary (family history of cancer) risk factors were included for univariate and multivariate logistic regression analyses, to analyze the association between serum HBsAg and cancers. In multivariate analysis, the associations of HBsAg and cancers were adjusted by potential confounding factors, including age (52/> 52 y, median 52 y), sex (Male/Female), year of diagnosis (2008-2010/2011-2012/2013-2014 other HBV-related cancers and other cancers, respectively. The detailed results for univariate and multivariate logistic regression analyses were shown in Table 2 .
The univariate and multivariate analyses were then repeated to identify specific non-hepatocellular cancers associated with serum HBsAg positivity ( Table 4 .
Median age at all-cause death was significantly younger for 5 years among serum HBsAg postitive cancer patients compared with serum HBsAg negative ones in the general cancer population, and consistent younger median ages at all-cause death were also found in above-mentioned various subgroups. For patients with HCC, those with positive serum HBsAg had a 9-year younger median age at all-cause death than those with negative serum HBsAg. For patients with other HBV-related cancers and other cancers, the median ages at all-cause death were respectively 5 and 3 years younger among serum HBsAg positive patients compared with serum HBsAg negative ones. To eliminate the influence of death from non-cancer causes, we repeated the analyses in patients died of cancer, and the results also supported a younger median age at cancer-specific death among serum HBsAg positive patients in the general population and in all subgroups. The detailed information for the comparisons of median age at all-cause death and cancer-specific death was shown in Table 4 .
We further compared the median age at diagnosis, all-cause and cancer-specific death between serum HBsAg positive and negative cancer patients in specific cancers with the 68,038 cancer cases which had available information for serum HBsAg. There were 16 of 21 cancers showing significant younger median age at diagnosis, and 10 of 21 with significant younger median age at death among serum HBsAg positive patients compared with serum HBsAg negative ones, ranging respectively from 1 to 8, and from 1 to 9 years. Consistently, median age at cancerspecific death in these cancers was also significantly younger among serum HBsAg positive patients. The detailed information for the comparisons of median age at diagnosis and median age at all-cause death as well as cancer-specific death in specific cancers was shown in Supporting Information Table 2 .
Detection of HBV DNA and HBcAg in gastric cancer tissues
We included 275 frozen gastric cancer tissues to detect the presence of HBV DNA with PCR. The positive rate of serum HBsAg was 14.2% in these 275 patients. As a result, HBV DNA was detected in 34 (12.4%) gastric cancer tissues, including 28 out of 39 (71.8%) patients with positive serum HBsAg, and 6 out of 213 (2.8%) patients with negative serum HBsAg. Representative PCR-amplification of HBV DNA was shown in Figure 1 
Discussion
The relation of HBV infection and cancer incidence is an appealing topic. Excepting for the definite role of HBV infection in HCC, the association of HBV infection with many cancers is still unclear. We reported that HBV infection might play an etiologic role in the induction of B-cell NHL. 3, 18 According to two recent cohort studies in Taiwan and South Korea, the risk for NHL was about 2-3 fold higher in HBV infected population compared with HBV noninfected population. 4, 5 In addition, pancreatic cancer and cholangiocarcinoma were also identified to be HBVassociated cancers by some epidemiological studies. [5] [6] [7] 19, 20 We also reported that HBV infection increased synchronous liver metastasis rate and was an independent prognostic factor in pancreatic cancer patients. 21 Moreover, there were some sporadic studies showing that HBV infection might be associated with gastric cancer, 12 nasopharyngeal carcinoma, 14 endometrial carcinoma 22 and distal colon adenoma. 23 Our study verified the modest but significant association with non-hepatocellular cancers, including NHL, pancreatic cancer, cholangiocarcinoma, gastric cancer and nasopharyngeal carcinoma, in a large cohort of Chinese patients. In addition, our study indicated that cervical cancer and brain cancer might be possibly HBV-related for the first time. We also found that for those with positive serum HBsAg, not only the age at cancer diagnosis, but also the age at all-cause death and cancer-specific death, were significantly younger than those with negative serum HBsAg.
Although some patients with occult hepatitis B virus infection may have persistence of HBV DNA in the liver tissue (and in some cases also in the serum) in the absence of circulating HBsAg, HBsAg is still a currently irreplaceable marker to evaluate the status of HBV infection. First, the occult hepatitis B virus infection is more often found in the patients with concomitant HCV infection. 24, 25 Second, the prevalence of HCV is relatively lower in Chinese population than in Western counties and Japan. As shown in Supporting Information Table 1 , the concomitant HCV infection rates in patients with positive and negative HBsAg were only 0.6% and 0.5%, respectively. But it is still important to pay attention to the existence of occult hepatitis B virus infection in clinical practice.
The role and mechanism of HBV infection in the carcinogenesis of HCC have been studied intensively. The integration of HBV DNA into the host genome can induce direct insertional mutagenesis of various cancer-related genes, and the subsequent chronic liver inflammation and hepatic regeneration induced by cellular immune responses may favor the accumulation of genetic alterations and result in the ultimate malignant transformation. In this study, we investigated the expression of HBV DNA and HBcAg in gastric cancer tissues. The results showed the objective evidence of existence of HBV in gastric cancer tissues. HBV DNA or HBV antigens had been detected in extra-hepatic organs or tissues, including spleen, kidney, skin, pancreatic tissues, bile duct epithelium, and peripheral blood cells. [26] [27] [28] [29] [30] HBcAg had been demonstrated to play an immunosuppressive role on T cells. 31, 32 We identified HBcAg most commonly in lymphocytes in gastric cancer tissues by immunohistochemical staining in our study. The further understanding of the impact of systemic immune dysfunction caused by HBV infection in non-hepatocellular cancers might provide a novel strategy to prevent them.
Most of the traditional therapies, including surgery, chemotherapy and radiotherapy can result in immunosuppression of cancer patients, which facilitates the reactivation of HBV and complicates the treatments. 33 Some targeted agents, particularly anti-CD20 monoclonal antibodies ofatumumab and rituximab, may also cause severe and fatal reactivation of HBV. 34 The reactivation of HBV during immunosuppressive drug therapy has drawn attention recently and many guidelines have been proposed for the prevention and treatment of this issue. [35] [36] [37] Therefore, the prevalence of HBV infection in a large cohort of cancer patients of our study provides a valuable reference to emphasize the importance of monitoring and management the underlying HBV infection during the anti-cancer therapies.
Collectively, our current study showed that HBV infection had a modest but significant nonspecific association with total non-hepatocellular cancers. And the HBV infection might also be associated with early occurrence of cancer and early death of cancer patients.
